Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
Darolutamide: New Standard of Care in Nonmetastatic CRPC?
Nubeqa Delays Prostate Cancer Progression in Resistant Prostate
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Prostate cancer - InDepth - SmartEngage
Darolutamide is a potent androgen receptor antagonist with strong
Cancers, Free Full-Text
Clinical Development of Darolutamide: A Novel Androgen Receptor
Patient education: Treatment for advanced prostate cancer (Beyond
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New
de
por adulto (o preço varia de acordo com o tamanho do grupo)
